Breaking News

BioMarin Acquires PKU Franchise From Merck Serono

Gains rights to both Kuvan and pegvaliase beyond North America

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioMarin Pharmaceutical Inc. has acquired global rights to Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono. BioMarin will provide Merck with an upfront payment of €340 million. An additional €60 million in milestones will be paid to Merck if combined sales of Kuvan and pegvaliase reach undisclosed cumulative sales thresholds. In addition, €125 million will be paid to Merck for regulatory milestones related to pegvaliase. Previously, BioMarin had exclusive rights to Kuvan in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters